---
title: "IFE Elevators: Net profit of 34.0587 million yuan in the first half of 2025, a year-on-year decrease of 43.04%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/254843116.md"
description: "IFE Elevators announced that in the first half of 2025, operating revenue was 625 million yuan, a year-on-year decrease of 10.83%. Net profit was 34.0587 million yuan, a year-on-year decrease of 43.04%. The company plans not to distribute cash dividends, not to issue bonus shares, and not to increase capital by converting reserves"
datetime: "2025-08-27T14:12:22.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/254843116.md)
  - [en](https://longbridge.com/en/news/254843116.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/254843116.md)
generator: "portal-rs"
---

# IFE Elevators: Net profit of 34.0587 million yuan in the first half of 2025, a year-on-year decrease of 43.04%

IFE Elevators announced that in the first half of 2025, operating revenue was 625 million yuan, a year-on-year decrease of 10.83%. Net profit was 34.0587 million yuan, a year-on-year decrease of 43.04%. The company plans not to distribute cash dividends, not to issue bonus shares, and not to increase capital through reserves

### Related Stocks

- [002774.CN](https://longbridge.com/en/quote/002774.CN.md)

## Related News & Research

- [North Sea Crude-WTI weakens on lower offer](https://longbridge.com/en/news/296813963.md)
- [Icelandic Salmon posts H1 2026 financial report](https://longbridge.com/en/news/296863293.md)
- [Kaldvik to webcast Q2 2026 results presentation with CEO, CFO speakers](https://longbridge.com/en/news/296784145.md)
- [09:22 ETAfecta Pharmaceuticals Granted New US Patent for Neuro-Immuno Modulators](https://longbridge.com/en/news/296921568.md)
- [Focus Graphite and C4V to Evaluate Mine-to-Anode Platform Combining Lac Knife Graphite with C4V's Green Anode Technology | FCSMF Stock News](https://longbridge.com/en/news/297014309.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**